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Zheng et al. find that wild-type N-Ras,
overexpressed in basal-like breast
cancer, promotes tumor formation by
activating cytoplasmic JAK2, leading to
IL-8 induction. This stimulates cancer
cells themselves and possibly also
stromal fibroblasts, thus creating a
proinvasive microenvironment.
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Basal-like breast cancers (BLBCs) are aggressive,
and their drivers are unclear. We have found that
wild-type N-RAS is overexpressed in BLBCs but not
in other breast cancer subtypes. Repressing N-RAS
inhibits transformation and tumor growth, whereas
overexpression enhances these processes even in
preinvasive BLBC cells. We identified N-Ras-respon-
sive genes, most of which encode chemokines; e.g.,
IL8. Expression levels of these chemokines and
N-RAS in tumors correlate with outcome. N-Ras,
but not K-Ras, induces IL-8 by binding and activating
the cytoplasmic pool of JAK2; IL-8 then acts on both
the cancer cells and stromal fibroblasts. Thus, BLBC
progression is promoted by increasing activities of
wild-type N-Ras, which mediates autocrine/para-
crine signaling that can influence both cancer and
stroma cells.INTRODUCTION
Approximately 20% of breast cancers belong to the ‘‘basal-like’’
subtype. Basal-like breast cancers (BLBCs) are of great clinical
importance because they are the most aggressive breast can-
cers, with very poor prognosis (Sorlie et al., 2003). These tumors
are commonly ‘‘triple negative,’’ lacking estrogen receptor (ER),
HER2, and progesterone receptor; as such, they cannot be
treated by current targeted therapies, which are largely directed
against ER or HER2. Thus, it is urgent to identify drivers for BLBC
that can be targeted in order to treat this aggressive form of
breast cancer.The basal-like tumors are so named because they express
markers typical of the cells in the basal layer in the mammary
duct (Perou et al., 2000), approximately 1% of whose cells are
postulated to have stem/progenitor cell properties. BLBC cells
and human embryonic stem cells (ESCs) have been found to ex-
press a common set of genes (Ben-Porath et al., 2008), suggest-
ing that the BLBC cells are enriched with cells having stem cell
properties. We have thus sought to identify a common growth
mechanism in these cells that may lead to the discovery of a
driver for BLBC.
Humans have three RAS genes, H-, N-, and K-RAS, and
the latter can undergo alternative splicing to produce two
isoforms: K-Ras-4A and K-Ras-4B. As a result, human cells
have a total of four Ras proteins. Oncogenic RAS mutations
are among the most-frequent genetic alterations in human
tumors—over 30% of all human tumors contain an oncogenic
RAS mutation (Pylayeva-Gupta et al., 2011). In breast cancers,
however, oncogenic RAS mutations are rare (Bos, 1989).
But different wild-type RAS genes are selectively overex-
pressed in different subtypes of human breast cancer
cells (Hoadley et al., 2007)—BLBC cells selectively over-
express N-RAS, whereas luminal breast cancer cells selec-
tively overexpress H-RAS, suggesting that the gain of activity
of a particular wild-type Ras protein might play a key role in
promoting the development of these subsets of breast
cancers.
In this study, we present evidence that N-Ras is a
driver for BLBCs. By analyzing genes whose expression
is N-Ras dependent, we illustrate a key mechanism by
which N-Ras can promote BLBCs, namely it activates Janus
kinase 2 (JAK2), leading to interleukin-8 (IL-8/CXCL8) induc-
tion, which stimulates not only cancer cells themselves but
possibly also stromal fibroblasts to create a proinvasive
microenvironment.Cell Reports 12, 511–524, July 21, 2015 ª2015 The Authors 511
Figure 1. N-RAS Is Selectively Overexpressed in BLBCs, and Its Expression Levels Associate with Clinical Outcome
(A) Box-whisker plots of N-RAS expression levels in different breast cancer subtypes from RNA-seq data in TCGA. AU, arbitrary unit; BL, basal-like; Her2, Her2
positive; LumA, luminal A; LumB, luminal B; N, normal adjacent tissues; NL, normal like. p value is by ANOVA.
(B)N-RASmRNA in the indicated breast cancers or tissues (A) correlatedwithN-RAS promotermethylation in the same TCGAdata sets. p value is by Spearman’s
correlation.
(C) N-Ras protein levels in different subtypes of breast cancer cell lines (n, number of cell lines; see Supplemental Information) were measured by western blot.
(D) N-Ras in tumors from indicated PDXs, relative to normal mouse mammary tissues, analyzed by western blot as above.
(E) Kaplan-Meier plots of breast-cancer-specific survival in patients (n = 1,970) by tertiles (high, medium, and low levels) of N-RASmRNA levels over time in the
METABRIC data set. p value is by log rank test.
All data in (C) and (D) are presented as mean ± SEM. See also Figure S1.RESULTS
N-RAS Is Selectively Overexpressed in BLBCs
As mentioned above, N-RAS has been shown to be selectively
overexpressed in BLBC cell lines. In this study, we first deter-
mined whether in human breast cancers N-RAS is also selec-
tively overexpressed. Upon examining The Cancer Genome
Atlas (TCGA) RNA-seq data (Cancer Genome Atlas Network,
2012), we found that N-RAS expression levels are highest in
BLBCs and lowest in normal adjacent tissues (Figure 1A).
N-RAS expression seems to negatively correlate with expression
of ESR1 (encoding the ER-a; r = 0.27; p = 8.4 3 107 Spear-
man’s rank correlation), ERBB2/HER2 (r = 0.19; p = 3 3
104), and PGR (encoding the progesterone receptor; r =
0.23; p = 2.4 3 105). Other microarray data sets (Prat et al.,
2010) reinforce these observations (Figure S1A). Furthermore,
we found that N-RAS mRNA levels inversely correlate with
N-RAS promoter methylation (Figure 1B), supporting the possi-
bility that N-Ras overexpression may be partly mediated by
epigenetic demethylation at the N-RAS promoter.512 Cell Reports 12, 511–524, July 21, 2015 ª2015 The AuthorsTo determine whether N-Ras is overexpressed in BLBCs at
the protein level, we used western blot to analyze a large
collection of human breast cancer cell lines that recapitulates
the molecular complexity seen in human breast tumors (Neve
et al., 2006). As shown in Figure 1C, BLBC cells express
approximately four times more N-Ras protein than do luminal
breast cancer cells, leading to more GTP-N-Ras in the former
(Figure S1B). In addition, the N-Ras levels in BLBC cells are
higher than those of H- and K-Ras. In contrast, luminal breast
cancer cells have more H-Ras than N- and K-Ras proteins,
agreeing with our previous study examining the mRNA levels
(Hoadley et al., 2007). We also examined several patient-
derived xenograft (PDX) lines, the tumors in which preserve
key pathological features and biomarkers of the original tu-
mors (Zhang et al., 2013), and found that basal-like PDXs
have more N-Ras than ER+ PDXs (Figure 1D). Finally, in sup-
port of the concept that human ESCs and BLBCs express a
similar set of genes, we examined two human ESC lines and
found that they too express more N-Ras than K- and H-Ras
(Figure S1C).
N-Ras Levels and Outcome
To determine whether N-Ras expression levels are important for
breast cancer, we searched databases with patient outcome
information. As shown in Figure 1E, we found that high N-RAS
expression levels associate with poor breast-cancer-specific
survival in the METABRIC data sets (Curtis et al., 2012). We
also examined another database (Prat et al., 2010) and came
to the same conclusion (Figure S1D). We note that, in all our
bioinformatics analyses, high N-RAS mRNA levels are insepa-
rable from the basal-like subtype, which supports the concept
that high N-Ras levels drive the formation of this subtype of
breast cancer. To further examine whether N-Ras levels can in-
fluence outcomewithin BLBCs, we analyzed the aforementioned
PDXs (Figure 1D) and found that basal-like PDXs that are meta-
static in mice have higher levels of N-Ras protein than those
basal-like PDXs that are not metastatic. We conclude that
BLBCs selectively overexpress primarily one of the Ras pro-
teins, N-Ras, and that high levels of N-Ras associate with poor
outcome.
N-Ras, but Not K-Ras, Is Required for Efficient Growth of
Just BLBC Cells
To determine whether selective N-Ras overexpression in BLBCs
is functionally relevant, we repressed N-RAS by shRNA (clone
no. 1) by 70%–90% in all the examined cell lines (Figure 2A)
without affecting levels of H-Ras, K-Ras, and GAPDH. When
N-Ras was so suppressed, only the growth of BLBC cells was
greatly inhibited (50%–80% reduction; Figure 2B), whereas the
growth of luminal breast cancer cells and untransformed
‘‘normal’’ breast mammary epithelial cells was not significantly
impacted (Figure 2B). Like BLBCs, claudin-low cells are also
frequently triple negative (Prat et al., 2010), and their N-Ras pro-
tein levels are not statistically different from those of BLBC cells
(Figure 1C). Surprisingly, however, N-RAS repression did not
affect the growth of the claudin-low cell lines (Figures 2B and
S2A). To further assess any possible off-target effects of gene
silencing in BLBC, we overexpressed anN-RAS cDNA refractory
to this shRNA (N-RAS*) and found that it rescued the growth in-
hibition in N-RAS-repressed basal-like cells (Figure 2C). Using
two additional shRNA clones (no. 2 and no. 3), we came to the
same conclusion (Figures S2A and S2B).
We also examined K-RAS and found that K-RAS repression
(Figure 2A) did not affect cell growth (Figure 2B) and that
K-RAS overexpression did not rescue the growth inhibition of
N-RAS-repressed basal-like cells (Figure 2C). These data sug-
gest that most BLBC cell lines not only selectively overexpress
N-Ras but also depend on N-Ras, but not K-Ras, for efficient
cell growth. Finally, we found that human ESCs are also depen-
dent on N-Ras for proliferation (our unpublished observation).
Efficient Transformation of BLBC Cells Is Dependent on
N-Ras
We first examined colony formation in soft agar (anchorage-in-
dependent growth) and found that this activity was inhibited
by N-RAS repression in two malignant BLBC cell lines (MDA-
MB-468, Figure 2D, and SUM149PT, Figure S2C), but not in
claudin-low cell lines (MDA-MB-231, Figure 2D, and SUM159PT,
Figure S2C). We also examined a preinvasive BLBC cell line,SUM102PT, which was derived from intraductal carcinoma
and shows ductal carcinoma in situ (DCIS) features in 3D culture
(Jedeszko et al., 2009; Kaur et al., 2012). SUM102PT cells are
only weakly transformed and do not efficiently form colonies in
soft agar. Colony formation is induced, however, when these
cells are co-cultured with human mammary fibroblasts (HMFs),
a key component of the stroma (Figure 2D). When N-RAS was
silenced in SUM102PT cells, their ability to form colonies in
soft agar even co-cultured with HMFs was also greatly inhibited.
Similar results were observed using two other shRNAs (Figures
S2D and S2E). We also examined cell invasiveness and found
that it was decreased by N-RAS knockdown only in the basal-
like MDA-MB-468 cells, but not in the claudin-low MDA-MB-
231 cells (Figure 2E). This defect was similarly rescued by the
shRNA-resistant N-RAS*, suggesting that the gene silencing is
also selective when cell invasion is measured.
Whereas N-Ras is not essential for growth and transformation
of claudin-low cells, N-RAS-repressed claudin-low cells, but
not BLBC cells, appeared morphologically smaller after pro-
longed culturing in vitro (our unpublished results). Thus, although
claudin-low and BLBC cells are both usually triple negative,
increasing evidence supports their classification into two
different subtypes (Herschkowitz et al., 2012), and it seems
that one key difference between them is how the cells react
to N-Ras.
N-Ras Is Required for Efficient Tumor Formation and/or
Tumor Growth of BLBC Cells
To determine whether N-Ras is required for BLBC cells to form
tumors in vivo, we first examined SUM102PT cells, which can
form tumors when co-transplanted with HMFs into mice (Fig-
ure 2F). However, whenN-RASwas silenced in SUM102PT cells,
tumor latency increased, and the tumor number (Figure 2F), as
well as tumor volume (Figure S2F), decreased. Similar results
were obtained using shRNA-3 (Figure S2G), which was made
into an inducible vector (Figure S2B). The effect of shRNA-3 on
tumor formation can be rescued by wild-type N-RAS (shRNA-3
targets a non-coding region; Figure S2G), suggesting that the
observed growth inhibition is caused by N-RAS repression
with a high degree of selectivity. A similar growth inhibition was
observed when N-RAS-repressed malignant MDA-MB-468 cells
were transplanted into mice (Figures 2G and S2H). To further
examine N-Ras’s role in BLBC, we switched off N-RAS expres-
sion after tumors were detectable and found that their growth
was substantially decreased (Figure 2H).
N-Ras Overexpression Promotes Transformation of
BLBC Cells
To ascertain whether N-Ras can promote the development of
BLBCs, we first overexpressed it in the malignant basal-like
MDA-MB-468 and BT20 cells and found that their ability to
form colonies in soft agar was readily enhanced (Figure 3A); in
contrast, N-Ras overexpression did not enhance colony forma-
tion of the claudin-low MDA-MB-231 and SUM159PT cells. To
more stringently test the concept that N-Ras can drive BLBC,
we overexpressed it in the preinvasive SUM102PT cells and
found that colony formation in soft agar was increased even
without HMFs (Figure 3B). Finally, we overexpressed N-Ras inCell Reports 12, 511–524, July 21, 2015 ª2015 The Authors 513
Figure 2. N-Ras Is Required for Efficient Growth, Transformation, and Tumor Formation of BLBC Cells Only
(A) Cells expressing control or shRNAs targeting N-RAS or K-RAS4B were analyzed by western blot for Ras proteins using isoform-specific antibodies. GAPDH
was the loading control. The numbers below the blot indicate protein levels relative to the non-silenced control.
(legend continued on next page)
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the untransformed basal-like MCF10A cells and found that they
too were transformed after a relatively long latency (Figure 3C).
We also examined whether N-Ras overexpression can promote
cell migration and invasion in the preinvasive SUM102PT
and normal MCF10A cells. As shown in Figure 3D, N-Ras
did enhance migration of these two cell lines, but not invasion
(Figure S3A).
N-Ras Overexpression Promotes Tumor Formation in
Mouse Models of BLBC
To determinewhether N-Ras overexpression can promote tumor
formation, we first investigated SUM102PT cells, which weakly
form tumors in mice when co-transplanted with HMFs. Overex-
pressing N-Ras in SUM102PT cells shortened the latency for
tumor formation, which correlated with an increase in tumor
growth rate (Figure 3E).
Like N-Ras, the canonical Wnt pathway in BLBC is not
frequently mutated, but its activity is upregulated, which predicts
poor outcome (Khramtsov et al., 2010). In mice, MMTV-Wnt1
efficiently induces hyperplastic early lesions and tumors do
eventually emerge after a long latency (Tsukamoto et al.,
1988). These tumors resemble human BLBC (Herschkowitz
et al., 2007). Intriguingly, it has been known for some time that
50% of the mammary tumors arising in MMTV-Wnt1 trans-
genic mice carry oncogenic mutations affecting ras (Podsypa-
nina et al., 2004). Examining the other half of the tumors, those
without oncogenic ras mutations, we found that they have very
high levels of N-Ras (Figure S3B). We then went on to construct
an inducible vector to overexpress N-Ras in MMTV-Wnt1 mice
and found that N-Ras overexpression accelerated tumor forma-
tion (Figure 3F).
Identifying N-Ras-Dependent Genes
To uncover the role of N-Ras specifically in BLBC cells, we
repressed N-RAS expression and then profiled gene-expression
changes in two different basal-like cell lines (SUM102PT and
SUM149PT). We also similarly analyzed a claudin-low cell line
(SUM159PT) as control because its growth is not sensitive to
N-RAS-repression. As shown in Table S1 (GEO: GSE61768),
despite the fact that the two BLBC cell lines are different,
N-RAS repression readily induced changes of expression of a
similar set of genes, whereas such changes were not detected
in the claudin-low cells. We then used this gene set to search(B) Cells were transduced by the shRNAs as in (A), and the growth rates were m
(C) An N-RAS cDNA refractory to shRNA (N-RAS*) or a K-RAS4B cDNA was over
were measured (top), and indicated proteins were analyzed by western blot (bot
(D) Cells were transduced by shRNAs as in (A) and seeded either alone or togeth
(E) N-RAS in indicated cells was similarly silenced as above with or without N-RA
western blot (right).
(F) Control orN-RAS-repressed SUM102PT cells were injected with HMFs into nu
control. Kaplan-Meier curves of the portion of tumor-free animals are shown on th
tissue was confirmed by RT-PCR (right). p value (Gehan-Breslow-Wilcoxon test)
(G) Control or N-RAS-repressed MDA-MB-468 cells carrying luciferase were inje
group; n = 10 tumors). Their luciferase activity (Figure S2I) was measured weekly (
N-RAS silencing in the tissue was confirmed by RT-PCR (right).
(H) SUM102PT cells carrying the inducibleN-RAS shRNAwere co-injectedwith HM
mice were treated with doxycycline (DOX) or the vehicle control and the tumor s
All data are presented as mean ± SEM. See also Figure S2.against the Molecular Signature Database (MSigDB) to reveal
the biological pathways in which they are involved (Table S2).
Strikingly, those genes whose expression is downregulated
when N-RAS is repressed appear to be enriched for genes
involved in immune/inflammatory responses, e. g., cytokines
and chemokines. Conversely, genes that are upregulated dur-
ing N-RAS repression are enriched for markers of differentiation
or development (e.g., keratins, collagens, and cytoskeletal
proteins).
N-RAS-Controlled Genes Are Clinically Relevant and
Associate with Clinical Outcome
To ascertain whether the genes identified above using cell lines
may also be controlled by N-Ras in human tumors, we asked
whether there was any correlation in the expression levels be-
tween N-RAS and the identified genes in several databases of
human tumors. As shown in Table 1, in the METABRIC data
set, we found a good correlation in expression levels between
N-RAS and genes that were downregulated, but not with those
that were upregulated, when N-RAS expression was sup-
pressed. Expression of neither set of genes correlated with those
of K-RAS. These conclusions were supported by examining
another database (Prat et al., 2010). For the rest of the study,
we thus focused on those genes that are downregulated when
N-RAS expression itself is also downregulated.Wewill call these
the ‘‘down’’ genes hereafter.
We selected those down genes whose levels were changed
R2-fold for validation by qPCR. As summarized in Figure 4A,
the expression of these six genes is dependent on N-RAS, but
not on K-RAS, in the basal-like cell lines, but not in the control
claudin-low cell lines. Finally, expression of these validated
genes returned nearly the same correlation with N-RAS
expression levels in human tumors as shown in Table 1. We
will call these six genes in Figure 4A ‘‘N-Ras-responsive genes’’
hereafter.
To determine whether these N-Ras-responsive genes are also
clinically relevant, we first analyzed a published database in
which gene expression in normal, DCIS, and invasive ductal car-
cinoma (IDC) was profiled (Knudsen et al., 2012) and found that
the sums of the expression levels of these six N-Ras-responsive
genes aremuch higher in DCIS or IDC than in normal tissues (Fig-
ure 4B). Consistent with the observation that metastatic PDXs
have higher levels of N-Ras (Figure 1D), there is an intriguingeasured.
expressed in N-RAS-silenced SUM102PT cells. The growth rates of these cells
tom). The numbers below indicate protein levels relative to the controls.
er with HMFs (1:1) in soft agar.
S* and examined for invasiveness (left). N-Ras in these cells was analyzed by
demice (n = 6). The control cells were also injected alone (n = 6) as an additional
e left whereas pictures of mice are shown in the middle. N-RAS silencing in the
was calculated between the green and red curves.
cted into nude mice (two mammary glands per mouse and five mice in each
left) to calculate the tumor growth rates (between week 8 and week 13, middle).
Fs (1:1) into nudemice (n = 9). When tumors became detectable (arrow), these
ize was measured twice per week.
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Figure 3. N-Ras Overexpression Promotes Transforming Activities and Tumor Growth of BLBC Cells
(A) Control or N-Ras-overexpressing cells were seeded in soft agar for colony formation.
(B) Control or N-Ras-overexpressing SUM102PT cells were seeded in soft agar alone or with HMFs (2:1) for the indicated durations (left). N-Ras overexpression
was confirmed by western blot (right).
(C) N-Ras was similarly overexpressed inMCF10A cells and seeded in soft agar. Colony number wasmeasured 2months later (left). Western blot validated N-Ras
overexpression (right).
(D) Control or N-Ras-overexpressing cells were measured for their migration abilities.
(E) Control or N-Ras-overexpressing SUM102PT cells were co-injected with HMFs (2:1) into nudemice (n = 10mice). A Kaplan-Meier plot of the portion of tumor-
free mice over time is shown on the left (p value by Gehan-Breslow-Wilcoxon test), whereas a plot of tumor volumes over time is shown in the middle.
Overexpression of the human N-RAS in the tissue was confirmed by RT-PCR (right).
(F) An inducible N-RAS vector was injected into the mammary glands of 26 MMTV-Wnt1 mice, which were then randomized to receive DOX or water, and the
portion of tumor-free mice was plotted over time. p value is by Gehan-Breslow-Wilcoxon test (left). Levels of N-Ras (middle), JAK2, and phospho-JAK2 (right) in
seven tumors from the +DOX group (n = 7) and four tumors untreated by DOX (n = 4) were examined by western blot.
All data are presented as mean ± SEM. See also Figure S3.trend here that the expression levels of these genes are higher in
IDC thanDCIS (Figure 4B), but the differences are not statistically
significant. We obtained the same results after examining
another database (Lee et al., 2012).
In addition, we interrogated several data sets with clinical out-
comes as described earlier. Upon analyzing the METABRIC
database, we found that expression levels of these N-Ras-res-
ponsive genes, like those of N-RAS itself, significantly associate
with breast-cancer-specific survival (Figure 4C). We obtained
the same results using the list of all the down genes (Table S1),
suggesting that these validated genes represent the key
signaling output of just N-Ras in BLBCs.We have also performed
principal-component analysis on another data set (Prat et al.,
2010) and come to the same conclusion (Figure S4A). These516 Cell Reports 12, 511–524, July 21, 2015 ª2015 The Authorsdata support the concept that activity from this N-Ras pathway
can promote progression of BLBCs, leading to poor outcome.
IL-8, a Key N-Ras-Responsive Gene, Stimulates Cancer
Cells in an Autocrine Fashion
The N-Ras-responsive genes encode mostly cytokines and
chemokines, which are secreted signaling molecules that may
stimulate growth of cancer cells in an autocrine fashion. To
test this, we prepared conditioned media from control or
N-RAS-repressed BLBC cells and found that the latter could
not efficiently support the growth of parental cells (Figure 5A).
Among the identified chemokines, we noticed that IL-8, like
N-RAS, is overexpressed in BLBCs and correlates with poor
outcome (Hartman et al., 2013; Rody et al., 2011; Figure S5A).




r p r p
Down 0.4 2.2 3 1016 0.0 0.1
Up 0.0 0.9 0.1 1.5 3 106
an = 1,992 tumors (METABRIC database)
bMedian-weighted expression levels of all the genes that are down- or
upregulated when N-RAS expression is repressed (Table S1) were
separately analyzed by Pearson correlation to determine whether these
correlated with expression ofN-RAS and K-RAS. In addition, we similarly
analyzed just those six genes validated to be downregulated uponN-RAS
repression (Figure 4A) and found that their expression levels also corre-
lated with those of N-RAS (r = 0.3; p = 2.2 3 1016), but not with K-RAS.Furthermore, IL-8 has been shown to be a Ras-induced gene
elsewhere (O’Hayer et al., 2009; Sparmann and Bar-Sagi,
2004), suggesting that activating IL-8 induction may be a core
Ras function. We first performed ELISA to measure IL-8 in the
culturemedia of breast cancer cell lines of various subtypes (Fig-
ure 5B). In agreement with the aforementioned microarray and
qPCR results, IL-8 levels were greatly reduced when N-RAS
was repressed in BLBC cells, but not in luminal and claudin-
low cells. We thus repressed IL8 using several shRNAs targeting
the non-coding region (Figure S5B) and found that the growth of
BLBC cells was readily inhibited, which can be rescued by over-
expressing IL8 (Figure 5C). To determine whether IL-8 acts on
known IL-8 receptors in cancer cells, we treated cells with the
IL-8 receptor antagonist repertaxin, which recapitulated the
selective growth inhibition of BLBC cells caused by shRNAs
against IL8 andN-RAS (Figure 5D). Conversely, adding recombi-
nant IL-8 (Figure 5E) or overexpressing IL8 (Figure S5C) partiallyrescued the growth defect caused by N-RAS repression. Finally,
as shown in Figure 5F, repressing IL8 by either shRNAs or reper-
taxin blocked soft agar colony formation selectively in BLBC
cells (but not in claudin-low cells). We note that adding back
IL-8 at the reported dosage only partially rescues the growth
defect caused by N-RAS repression. During the course of
analyzing the UNC337 database, we found that high mRNA
levels of CCL3, another N-Ras-responsive chemokine (Fig-
ure 4A), also associate with poor outcome (Figure S5D). When
CCL3 was added together with IL-8, the growth defect of
N-RAS-repressed cells was fully rescued (Figure 5E). These
data suggest that N-Ras controls the growth and transforming
activity of BLBC cells in an autocrine fashion by inducing chemo-
kines such as IL-8 and perhaps CCL3 as well.
N-Ras-Induced IL-8 Mediates Paracrine Signaling from
Cancer Cells to Mammary Fibroblasts
It is possible that N-Ras-induced cytokines/chemokines from the
cancer cells can also influence the tumor microenvironment by a
paracrinemechanism to impact tumorigenesis. In support of this,
we found that,whenN-RAS in cancer cellswas repressed,migra-
tionofHMFs towardBLBCcells, but not towardclaudin-lowcells,
was inhibited (Figure 5G). To determine whether IL-8 is a key
paracrine-signaling molecule, we performed co-culture experi-
ments with HMFs and measured soft agar colony formation.
Our data show that whereas soft agar colony formation of both
basal-like and claudin-low cells was enhanced by HMFs (Fig-
ure 2D), IL8 silencing or repertaxin treatment (Figure 5H), like N-
RAS silencing (Figure 2D), inhibited this activity only in BLBC
cells. To directly test that IL-8, produced in the cancer cells,
acts on the HMFs, we repressed the IL-8 receptor A or B in
HMF cells and found that soft agar colony formation of co-
culturedBLBCcellswasgreatly suppressed (Figures 5I andS5E).Figure 4. N-RAS-Controlled Genes Are
Clinically Relevant and Associate with
Outcome
(A) The mRNAs from basal-like cell lines
(SUM102PT and SUM149PT) and claudin-low cell
lines (SUM159PT and MDA-MB-231), transduced
by indicated shRNAs as in Figure 2A, were
analyzed with qPCR. The analysis of IL8 is shown
(left) as an example. The table on the right shows
the expression changes of indicated genes in
BLBC cells after being normalized to those in
claudin-low cells. See Table S1 for the list of all
the identified genes and Table S2 for MSigDB
analysis.
(B) The expression levels of the six N-Ras-
responsive genes were added up into a single
score, which was analyzed in the indicated breast
tissues.
(C) Kaplan-Meier curves of breast-cancer-specific
survival in patients by tertiles (high, medium, and
low levels) of the sum of expression levels of the
six N-Ras-responsive genes in the METABRIC
data set. p values are by log rank test.
All data are presented as mean ± SEM. See also
Figure S4.
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Figure 5. Functional Validation of N-Ras-Controlled Genes
(A) The growth media from control and N-RAS-repressed SUM102PT cells were mixed with fresh medium (1:1) and then added to parental SUM102PT cells for
measuring growth rate.
(legend continued on next page)
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Tumor fibroblasts, called carcinoma-associated fibroblasts
(CAFs), are emerging as a key stromal component that can pro-
mote tumor progression (Kharaishvili et al., 2014). The cell of
origin of CAFs remains unclear. A key type of CAFs displays my-
ofibroblast properties, e.g., expression of a-SMA. To define how
the N-Ras-IL8 pathway regulates HMFs, we investigated the
possibility that IL-8 secreted by BLBC cells can signal to HMFs
to induce myofibroblast-like properties by measuring a-SMA in-
duction. Indeed, as shown in Figure 5J, repressingN-RAS only in
BLBC cells led to a decrease of a-SMA level in the co-cultured
HMF cells, whereas directly adding recombinant IL-8 to HMF
increased it. These data are consistent with the possibility that
IL-8 induced by N-Ras in BLBC cells can promote myofibro-
blast/CAF-like properties in the fibroblasts.
Blocking IL-8 Suppresses Tumor Growth of BLBC Cells
IL-8 inhibitors are widely available and in clinical trials for treating
a wide range of diseases including cancers. We thus investi-
gated whether repertaxin as a single agent can efficiently block
tumor growth using the SUM102PT mouse model. As shown in
Figure 5K, repertaxin substantially reduced the rate of tumor
growth without affecting N-RAS expression levels. Thus, our re-
sults support the concept that repertaxin administered alone can
block the pathway downstream from N-Ras to impede growth of
BLBCs early in development.
N-Ras Controls IL-8 Induction by Activating JAK2
As shown earlier, repressing N-RAS expression inhibited IL-8
induction in BLBC cells. Conversely, when N-Ras was overex-
pressed, IL-8 levels increased (Figure 6A). IL-8 induction is
known to be driven by JAK2 (Britschgi et al., 2012); thus, we
asked whether N-Ras induces IL-8 via this known pathway. As
shown in Figure 3F, N-Ras overexpression can induce JAK2 acti-
vation (as measured by an increase in its auto-phosphorylation)
in mice. Conversely, when N-RAS was silenced in BLBC cells
(but not in claudin-low cells) in vitro, JAK2 activity was sup-
pressed (Figure 6B). JAK2 is known to activate STAT5 (Britschgi
et al., 2012; Wagner and Rui, 2008), and as shown in Figure 6C,
N-RAS repression also inhibited activation of STAT5 (but not
STAT3). In contrast, silencing K-RAS had no effect on JAK2/(B) The media collected from control or N-RAS-repressed cells were examined b
(C) Control or IL8-silenced SUM102PT cells, with or without IL8 overexpression,
(D) Growth rates of cells treated with the IL-8 receptor antagonist repertaxin rela
(E) SUM102PT cells were silenced as in Figure 2A and then treated with recombin
silenced cells. The growth rate of the non-silenced vehicle-treated cells was set
(F) (Left) The cells expressing control or IL8 shRNAs were seeded in soft agar for
with repertaxin.
(G) Migration of HMFs in response to the control or N-RAS-repressed cancer ce
(H) (Left) IL8 was similarly repressed as in (F), and the cells were seeded into soft
treated with repertaxin.
(I) SUM102PT cells were seeded in soft agar with IL8RA or IL8RB-silenced HMFs
the non-silenced controls set to 1 (left).
(J) HMFswere co-culturedwith control orN-RAS-repressed cells (left) or treatedw
GAPDH was the loading control. The numbers below indicate protein levels rela
(K) SUM102PT cells were co-injected with HMFs into nude mice (two mammary
tumor formation occurred (arrow), repertaxin was administered daily. Tumor siz
examined by RT-PCR (right).
All data are presented as mean ± SEM. See also Figure S5.STAT5 activation (Figure S6A). We also examined known Ras
effector pathways and found that N-RAS repression did not
affect Erk1/2 activation in BLBC cells (Figure S6B). N-Ras
repression did inhibit Akt phosphorylation (Figure S6B). How-
ever, inhibiting Akt by MK2206 did not affect JAK2 and STAT5
phosphorylation (Figure S6C), and N-Ras-overexpressed cells
are still sensitive to this compound (Figure S6D). These results
suggest that N-Ras mainly signals down JAK2 to activate
STAT5 in BLBC.
To determine whether activities induced by N-Ras overex-
pression are dependent on JAK2, we sought to block such activ-
ities by a JAK2 inhibitor (TG101348). N-Ras overexpression in
BLBC cells can either induce (SUM102PT cells) or enhance
(MDA-MB-468 cells) colony formation in soft agar. As shown in
Figure 6D, this activity was readily inhibited by TG101348. More-
over, MDA-MB-468 cells carrying just the vector control could
barely form colonies in soft agar when treated with TG101348
(50 colonies or so); however, when N-Ras was overexpressed
in these cells, close to 200 colonies could be seen with
TG101348. Thus, N-Ras overexpression apparently activates
more JAK2, making the cells four times more resistant to
TG101348. To further examine the impact of N-Ras on JAK2
activation, we measured IC50s of TG101348 in these BLBC cells
with or without N-Ras overexpression. As shown in Figure 6E,
N-Ras-overexpressed cells returned IC50s that are approxi-
mately three times greater than the cells with no N-Ras
overexpression. Conversely, when a constitutively active JAK2
(JAK2-(V617F)) was overexpressed, inhibition of cell growth
and soft agar colony formation by N-RAS repression were
rescued (Figure 6F). These data strengthen the concept that
N-Ras signals down JAK2 to control BLBC.
Physical Interactions between JAK2 and N-Ras
Whereas JAK2 activity is critical for many cancers, including
breast cancer, the mechanisms controlling this activity are not
well defined. We investigated the possibility that N-Ras can
directly activate JAK2 by physically binding to JAK2, using the
BiFC (bimolecular fluorescence complementation) method,
which we have employed to study Ras-effector interactions
(Cheng et al., 2011; Zheng and Chang, 2014; Zheng et al.,y ELISA for IL-8 (n = 3 separate experiments).
were seeded for growth rate measurement.
tive to those of vehicle (DMSO)-treated cells were measured.
ant IL-8 and/or CCL3 at concentrations that did not enhance the growth of non-
to 1.
colony formation. (Right) The cells were seeded into soft agar and then treated
lls.
agar with HMFs. (Right) The cells were co-seeded with HMFs in soft agar and
(right). The silencing was confirmed by western blot with IL-8 receptor levels in
ith IL-8 (right) for 7 days. HMF lysateswere analyzed bywestern blot for a-SMA.
tive to the controls.
glands injected per mouse and ten mice for each group; n = 20 tumors). When
e was measured every 5 days (left). Human N-RAS expression in tumors was
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2012a) due to its greater sensitivity to detect weak and transient
protein-protein interactions. In this system, one protein is fused
to an N-terminal fragment of YFP (Yn), whereas its binding part-
ner is fused to a C-terminal fragment of YFP (Yc). Binding of
these two proteins can bring Yn and Yc to close proximity to
facilitate refolding of a functional YFP detectable by FACS and
microscopy. As shown in Figure 6G, FACS analysis showed
that a YFP signal could be readily detected when Yc-JAK2
was paired with Yn-N-Ras, but not with Yn-GST or just Yn. Like-
wise, Yn-N-Ras and just Yc barely induced any YFP signals.
These data suggest that JAK2 and N-Ras interact with consider-
able specificity in this assay. Next, we investigated whether
the binding between N-Ras and JAK2 is dependent on the
effector-binding loop in N-Ras. We have previously created a
mutant Ras, RasDE, in which all amino acid residues in the
effector-binding loop were mutated to alanine, and its binding
to Raf-RBD was only half of that of wild-type N-Ras (Figure 6G).
Likewise, we found that JAK2 binding to N-Ras was also
reduced by half with N-RasDE. To assess whether the binding
between N-Ras and JAK2 is GTP dependent, we compared
the binding between wild-type N-Ras and a constitutively
GTP-bound N-Ras, N-Ras-(G12V), as well as the N-Ras-
(S17N) mutant, which is mostly GDP bound. As shown in Fig-
ure 6H, JAK2, like Raf, bound most strongly to N-Ras-(G12V)
and most weakly to N-Ras-S17N, suggesting that the binding
between N-Ras and JAK2 is largely GTP dependent.
JAK2, as well as the STAT proteins, is mostly cytoplasmic. In
fact, endogenous JAK2 is found almost exclusively in the cyto-
plasm (including the nucleus) but is not detectable at the plasma
membrane (Dawson et al., 2009). This mode of subcellular
localization has been later confirmed independently elsewhere
including in mammary cells (Dawson et al., 2011). Whereas
N-Ras and K-Ras-4B have an identical effector-binding loop,
we and others have shown that they localize to and signal from
different cell compartments—whereas a large portion of N-Ras
is cytoplasmic, K-Ras-4B is almost exclusively on the plasma
membrane (see Discussion). We thus analyzed the BiFC binding
by confocal microscopy to uncover where N-Ras and JAK2 bind
in the cell. As shown in Figure 6I, the binding between N-Ras andFigure 6. N-Ras Controls IL-8 Induction by Activating JAK2
(A) The media harvested from control and N-RAS-overexpressing SUM102PT ce
(B) The lysates of control or N-RAS-repressed cells (n = 3 triplicates) were analy
(C) The control and N-RAS-repressed cells were examined by western blot for in
(D) The control and N-RAS-overexpressed cells, which were treated with or with
(E) N-Ras was overexpressed as above, and the cells were treated with TG1013
(F) N-RAS-silenced cells were also transduced to express JAK2-(V617F) before
non-silenced control were measured. Protein expression levels were examined b
(G) HT1080 cells were transfected to express indicated Yn- and Yc-tagged prot
signal was detected by FACS (gated by untransfected cells as control), and an exa
and shown in the middle. Cells were also examined by western blot to show that t
(right).
(H) HT1080 cells carrying Yn- and Yc-tagged proteins were examined by FACS.
(I) HT1080 cells expressing Yn- and Yc-tagged proteins, as well as CFP-tagged
Rab7A for late endosomes), were examined by confocal microscopy.
(J) Cells overexpressing wild-type or palmitoylation-deficient N-Ras were seeded
proteins were expressed at comparable levels determined by western blot.
(K) MDA-MB-468 cells expressing indicated N-Ras proteins were treated with TG
All data are presented as mean ± SEM. See also Figure S6.JAK2 takes place mostly in the cytoplasm. These binding sites
appear as dots that are outside the nucleus and do not overlap
with Golgi or endosome markers. In contrast, N-Ras binds Raf
on the plasma membrane. As a control, we also examined
K-Ras-4B but quickly learned that it was more difficult to detect
its binding to JAK2. To boost the signal, instead of using thewild-
type version of the protein (as with N-Ras in Figure 6I), we used
the oncogenic K-Ras-4B-(G12V) and acquired the image using
up to three times more laser power. As shown in Figure 6I,
K-Ras-4B-(G12V) bound JAK2 almost exclusively at the plasma
membrane.
H- and N-Ras proteins must be palmitoylated at C-terminal
cysteine residues to be targeted to the plasma membrane. We
and others have shown that, when these proteins are restricted
to the cytoplasm by mutating these cysteines, the resulting
mutant Ras proteins can still transform cells and interact with
cytoplasmic effectors (Cheng et al., 2011; Chiu et al., 2002;
Zheng et al., 2012a). We expressed such a cytoplasm-restricted
N-Ras (N-Ras-(C181S)) and found that it can induce colony for-
mation in soft agar of BLBC cells as efficiently as wild-type Ras
(Figure 6J). Note that N-Ras-(C181S) can more efficiently induce
STAT5 activation, which is inhibited by TG101348 (Figure 6K).
These data strongly suggest that N-Ras is directly responsible
for activating the large cytoplasmic pool of JAK2 to promote
IL-8 induction in BLBCs.
DISCUSSION
BLBCs are aggressive, and their drivers are mostly unknown.
Our data suggest that the formation and/or progression of
BLBCs are driven by overexpressed wild-type N-Ras, a key
function of which is to activate JAK2, either alone or together
with the Wnt pathway. The activated JAK2 in turn induces
expression of a subset of cytokines and chemokines, such as
IL-8 and CCL3, in the cancer cells to stimulate tumorigenesis ac-
tivity in an autocrine fashion. These cytokines and chemokines
may also signal to stromal cells to create a proinvasive tumor
microenvironment in a paracrine fashion. Many components in
this N-Ras-chemokine and Wnt pathway have commerciallylls (n = 3 separate experiments) were analyzed for IL-8 by ELISA.
zed by ELISA for total and phosphorylated JAK2.
dicated proteins.
out TG101348, were seeded in soft agar for colony formation.
48 to measure IC50.
the growth rates (left) and colony formation in soft agar (middle) relative to the
y western blot (right).
eins and seeded into 96-well plates in triplicate (n = 3). The reconstituted YFP
mple of this is shown on the left. The percent YFP-positive cells was quantified
agged N-Ras and JAK2 are expressed at comparable levels in various samples
cell compartment markers (GalT for Golgi, Rab5A for early endosomes, and
in soft agar for colony formation (left). The right panel shows that both N-Ras
101348 for 16 hr and then examined by western blot.
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available inhibitors; thus, targeting them singularly or in combi-
nation may increase our chance to find an effective targeted
therapy for this devastating form of breast cancer.
Our data demonstrating that JAK2 is a potential N-Ras effector
in BLBC agree with previous findings linking N-Ras and JAK2 in
cancers. For example, the JAKs can be activated by the IL-6
receptor (Mihara et al., 2012), and in a multiple myeloma cell
line whose growth is IL-6-dependent, activated N-Ras can fully
replace IL-6 to promote growth and prevent apoptosis (Billadeau
et al., 1995). Similarly, oncogenic N-Ras requires JAKs to be fully
functional in leukemia (Kong et al., 2014). This apparent conver-
gence between N-Ras and JAK2 is intriguing considering they
are thought to be activated by different receptor families—Ras
by growth factor receptors and JAK2 by cytokine receptors.
Whether this N-Ras-JAK2 pathway is turned on by growth fac-
tors or cytokines or both is not resolved in this study, however.
Furthermore, whereas JAK2 can bind N-Ras in the BiFC assay,
it remains an open question whether such binding alone is suffi-
cient to activate JAK2 in BLBC. It is possible that, after binding to
Ras, JAK2 activation may be further mediated by cofactors.
These cofactors, as well as the upstream receptors, may control
the JAK2 pathway in a cell-type-dependent manner to partially
explain why JAK2 activation in claudin-low cells is not N-Ras
dependent.
Whereas K-RAS is the most frequently mutated RAS gene in
cancers, our data suggest that K-Ras is not required for growth
in BLBC cells. This selectivity can be partially explained by the
fact that there is approximately five times more N-Ras than
K-Ras in these cells (Figure 1C). However, we and others have
demonstrated that Ras proteins are not created equal and that
there may be real isoform-specific Ras activities in cancers.
For example, in a colon cancer mouse model, no colon cancer
can be seen when oncogenic K-RAS is replaced by knocked-
in oncogenic N-RAS (Haigis et al., 2008). One model to explain
the apparent Ras isoform-specific functions centers on the fact
that Ras protein structures diverge greatly at the C terminus,
which controls Ras subcellular localization. This has led to the
compartmentalized signaling model, whereby different Ras pro-
teins can signal to different pools of effectors that are spatially
compartmentalized in the cells (Chang and Philips, 2006; Cheng
and Chang, 2011; Fehrenbacher et al., 2009). Whereas K-Ras-
4B is found almost exclusively on the plasma membrane, a sub-
stantial amount of N-Ras is in the cytoplasm.We have previously
identified several cytoplasmic effectors that interact with N-Ras,
but not with K-Ras-4B (Zheng et al., 2012b). In this study, we
show that only N-Ras, but not K-Ras-4B, can efficiently activate
the cytoplasmic pool of JAK2. Considering that JAK2, as well its
effectors such as STAT5, is mostly cytoplasmic, it can be most
efficiently activated by the cytoplasmic pool of N-Ras without
having to be first translocated to the plasma membrane. We
must caution that it is inadequate to categorically suggest that
K-Ras is not important for BLBCs. During the course of identi-
fying N-Ras-dependent genes, we found that expression of
CXCL1, which encodes a critical factor for linking chemotherapy
resistance and metastasis (Acharyya et al., 2012), is also influ-
enced by K-Ras, suggesting that K- and N-Rasmay coordinately
regulate another set of genes that are important for breast
cancers.522 Cell Reports 12, 511–524, July 21, 2015 ª2015 The AuthorsIf breast cancer can be driven by wild-type N-Ras, it is baffling
why oncogenic N-RASmutations are rare in breast cancers. Our
gene expression data show that an oncogenic N-Ras influences
very few genes in common with those controlled by wild-type
N-Ras, such as IL-8 (Table S3; GEO: GSE61768; Figure S4B).
Thus, it is possible that an oncogenic N-Ras is not needed during
the early phase of breast tumorigenesis. Alternatively, blockage
in proliferation caused by oncogenic Ras-induced stresses, such
as DNA damage (Grabocka et al., 2014) and MAP kinase
pathway desensitization (Young et al., 2013), can be overcome
by wild-type Ras present in the same cell. We thus speculate
that an oncogenic N-RAS may occur early during breast tumor-
igenesis but is later lost once tumorigenesis begins to depend on
wild-type Ras and other oncogenic agents.
EXPERIMENTAL PROCEDURES
The following procedures can be found in Supplemental Information online:
cell lines and cell culture method; plasmid construction; transfection; microar-
rays; clinical data analyses; and measurement of proteins, cell transformation,
cell migration, and GTP-Ras.
Tumor Formation in Mice
All animal work was done in accordance with a protocol approved by the Bay-
lor College of Medicine Institutional Animal Care and Use Committee. Half a
million cancer cells, either alone or mixed with HMFs, were re-suspended in
Growth Factor-Reduced Matrigel (BD Biosciences) and PBS and injected
into the no. 4 and 9 mammary glands of 5- to 6-week-old female nude
mice (Harlan Laboratories). Tumor volume (mm3) was calculated by the
equation 0.5 3 (length) 3 (width)2. Tumor formation was recorded when it
was R30 mm3. To measure tumor growth by luciferase activity, MDA-MB-
468 cells were transduced with pWPT-FLuc-RFP and the RFP+-cells were iso-
lated by FACS, and their luciferase activity was measured as described (Wang
et al., 2015). ‘‘Total counts’’ were used to estimate tumor size. To block tumor
growth using repertaxin, tumor-bearing mice were randomized and given
repertaxin (Britschgi et al., 2012) when average tumor volume reached
30mm3. DOX (0.2 mg/ml) or water was given to mice when inducible expres-
sion vectors were used. The transgenicMMTV-Wnt1 mouse experiments were
performed as described (Bu et al., 2009; Li et al., 2000). Tumors were detected
by palpation three times a week. The initial detectable size is around 2 mm in
diameter, and the presence of tumor was further confirmed by monitoring its
growth. The presence of all tumors was later confirmed by Harris hematoxylin
and eosin staining.
Protein Binding Measured by BiFC
HT1080 cells, chosen for low autofluorescence, were co-transfected to ex-
press Yn and Yc fusion proteins, and 24 hr later, the protein binding was de-
tected as described (Zheng and Chang, 2014). Whereas we typically set the
argon laser power at 30% when acquiring images, we needed to use up to
80% laser power when examining the weak binding between Yn-K-Ras-4B-
(G12V) and Yc-JAK2.
Statistical Analysis
Data were examined by Student’s t test unless otherwise mentioned. Human
tumor databases were analyzed using the R statistical packages. All reported
p values were two-sided, unless otherwise indicated. p values for the IC50
measurement were determined by Software R with the DRC package. We
note that, throughout this paper, *p < 0.05, **p < 0.01, and NS is not significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.06.044.
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